Global Pharmaceutical Company Transforms Insider Risk with High Fidelity Metadata
A global pharmaceutical company, who employs more than 50,000 people, required a robust solution for protecting highly sensitive IP, including medical formulas, patient data, and promising scientific research.
Proactive insider risk management is critical to protecting sensitive IP from non-malicious, malicious, and compromised users. At the time of engaging with
DTEX, the company was seeking to elevate its insider risk capability through a fully-fledged program and required a technology that would enable early insider risk mitigation without stifling employee innovation.
